Novel Non-Steroidal Topicals in Plaque Psoriasis and Atopic Dermatitis—and the role of pharmacists

This CE lesson explores the evolving role of novel nonsteroidal topical therapies in the management of plaque psoriasis and atopic dermatitis. It reviews the mechanisms of action, efficacy and safety of tapinarof, roflumilast and ruxolitinib, and examines how these newer options fit within the treatment landscape. Pharmacists will gain practical guidance on selecting appropriate therapies, counselling patients, managing adverse effects, supporting adherence and using emerging evidence on long-term disease control and treatment-free intervals to optimize patient care. 

Course authors: Aaron Sihota, BSc (Pharm), RPh and Adam Natsheh, (Pharm), MD, FRCPC (Dermatology)

Accredited for 1.50 CEUs by the Canadian Council on Continuing Education in Pharmacy; CCCEP #1329-2026-4210-I-P

Learning Objectives:

1. Describe the role of novel non-steroidal topical therapies in plaque psoriasis and atopic dermatitis and the pharmacist’s role in supporting their appropriate use.
2. Explain the mechanisms of action of tapinarof (aryl hydrocarbon receptor agonist), roflumilast (phosphodiesterase-4 inhibitor), and ruxolitinib (Janus kinase 1/2 inhibitor).
3. Compare the efficacy and safety profiles of these novel non-steroidal topicals across indications using evidence from pivotal clinical trials.
4. Apply current evidence to guide product selection, application, safety monitoring, adherence, follow-up, and treatment planning across the disease spectrum.

This learning activity is supported by educational funding from Organon